Document is current

Any future updates will be listed below

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

Crossref DOI link: https://doi.org/10.1186/s40064-016-3024-5

Published Online: 2016-08-17

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark